Camilla Simpson, BSc, MSc

Camilla Simpson has more than 25 years of business and strategy experience across a diverse group of organizations from seed investments to public companies. Camilla has demonstrated a proven track record in delivering novel products for multiple disease indications to global markets in areas of high unmet medical need throughout her career. Currently, she is CEO of Zehna Therapeutics, Inc, a seed-stage start-up and spinout of the Cleveland Clinic. Prior to this, Camilla founded Rare Strategic LLC, where she provided strategic advice to early-stage venture-backed companies. She has held numerous executive leadership positions, including SVP, Head of Product Portfolio Development and Global Head of Regulatory Affairs at BioMarin Pharmaceutical Inc., and VP Global Regulatory Strategy – Early Development and Business Development at Shire Pharmaceuticals.